Gastroparesis| A Pipeline Analysis Report 2018| Technavio

Technavio has announced their latest pipeline analysis report on
the gastroparesis
market. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat gastroparesis.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180710005714/en/

Technavio has published a new report on the drug development pipeline for gastroparesis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio presents a detailed analysis of the market,
including regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market in the future.

THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME
ONLY: VIEW
MARKET SNAPSHOT BEFORE PURCHASING

Gastroparesis: Market overview

Gastroparesis is also known as delayed gastric emptying. It is a
disorder, which results in slowing down or stopping food movement from
stomach to small intestine due to improper or non-functioning of muscles
in the stomach. This further results in delayed digestion. Complications
of gastroparesis include dehydration, automatic loss of weight,
malnutrition, and fluctuation in sugar level, which becomes hard to
control.

According to a senior market research analyst at Technavio for research
on infectious and rare diseases, “As per a research, in the US,
around ten men and 40 women per 100,000 people have gastroparesis.
Moreover, the symptoms that are found to be similar to gastroparesis
occur in around one in four adults in the US.”

Gastroparesis: Segmentation analysis

This pipeline analysis report segments the gastroparesis market based on
drug development strategies (gastroparesis, diabetic or idiopathic
gastroparesis, and diabetic gastroparesis), therapies employed
(monotherapy), MoA (5-HT4 agonist and 5 HT3 antagonist, dopamine
receptor antagonist, nitric oxide donor, ghrelin receptor agonist,
?-opioid receptor antagonist, and neurokinin 1 receptor antagonist),
geographical segmentation (EMEA, APAC, and Americas), and recruitment
status (recruiting, completed, not yet recruiting, and enrolling by
invitation). It provides an in-depth analysis of the prominent factors
influencing the market, including drivers, opportunities, trends, and
industry-specific challenges.

LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST
A FREE SAMPLE REPORT

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005714/en/

Leave a Comment